This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Doñate, F. Articles by Mazar, A. P. Search for Related Content PubMed PubMed Citation Articles by Doñate, F. Articles by Mazar, A. P.

Peptides Derived from the Histidine-Proline Domain of the Histidine-Proline-Rich Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities

¹ Attenuon, LLC, San Diego, California; ² Division of Molecular Biology and Biochemistry, School of Biological Sciences, University of Missouri–Kansas City, Kansas City, Missouri; and ³ D. E. Shaw Research and Development, LLC, New York, NY

The antiangiogenic activity of the multidomain plasma protein histidine-proline-rich glycoprotein (HPRG) is localized to its histidine-proline–rich (H/P) domain and has recently been shown to be mediated, at least partially, through binding to cell-surface tropomyosin in fibroblast growth factor-2-activated endothelial cells (X. Guan et al., Thromb Haemost, in press). HPRG and its H/P domain, but not the other domains of HPRG, bind specifically and with high affinity to tropomyosin. In this study, we characterize the interaction of the H/P domain with tropomyosin and delineate the region within the H/P domain responsible for that interaction. The H/P domain of HPRG consists mostly of repetitions of the consensus sequence [H/P][H/P]PHG. Applying an in vitro tropomyosin binding assay, we demonstrate that the synthetic peptide HHPHG binds to tropomyosin in vitro and inhibits angiogenesis and tumor growth in vivo. The affinity for tropomyosin increases exponentially upon multimerization of the HHPHG sequence, with a concurrent increase in antiangiogenic activity. Specifically, the tetramer (HHPHG)₄ has significant antiangiogenic activity in the Matrigel plug model (IC₅₀ 600 nM) and antitumor effects in two syngeneic mouse tumor models. Thus, we show that a 16-mer peptide analogue mimics the antiangiogenic activity of intact HPRG and is also able to inhibit tumor growth, suggesting that cell surface tropomyosin may represent a novel antiangiogenic target for the treatment of cancer.

This article has been cited by other articles:

				F. Donate, G. C. Parry, Y. Shaked, H. Hensley, X. Guan, I. Beck, Z. Tel-Tsur, M. L. Plunkett, M. Manuia, D. E. Shaw, et al. Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth Clin. Cancer Res., April 1, 2008; 14(7): 2137 - 2144. [Abstract] [Full Text] [PDF]

				P. Gunning, G. O'neill, and E. Hardeman Tropomyosin-Based Regulation of the Actin Cytoskeleton in Time and Space Physiol Rev, January 1, 2008; 88(1): 1 - 35. [Abstract] [Full Text] [PDF]

				T. Sakai, K. Balasubramanian, S. Maiti, J. B. Halder, and A. J. Schroit Plasmin-Cleaved {beta}-2-Glycoprotein 1 Is an Inhibitor of Angiogenesis Am. J. Pathol., November 1, 2007; 171(5): 1659 - 1669. [Abstract] [Full Text] [PDF]

				I. Chung, M. K. Wong, G. Flynn, W.-d. Yu, C. S. Johnson, and D. L. Trump Differential Antiproliferative Effects of Calcitriol on Tumor-Derived and Matrigel-Derived Endothelial Cells. Cancer Res., September 1, 2006; 66(17): 8565 - 8573. [Abstract] [Full Text] [PDF]

				D. Sun and K. R. McCrae Endothelial-cell apoptosis induced by cleaved high-molecular-weight kininogen (HKa) is matrix dependent and requires the generation of reactive oxygen species Blood, June 15, 2006; 107(12): 4714 - 4720. [Abstract] [Full Text] [PDF]

				M. Vanwildemeersch, A.-K. Olsson, E. Gottfridsson, L. Claesson-Welsh, U. Lindahl, and D. Spillmann The Anti-angiogenic His/Pro-rich Fragment of Histidine-rich Glycoprotein Binds to Endothelial Cell Heparan Sulfate in a Zn2+-dependent Manner J. Biol. Chem., April 14, 2006; 281(15): 10298 - 10304. [Abstract] [Full Text] [PDF]

				J. Dixelius, A.-K. Olsson, A. Thulin, C. Lee, I. Johansson, and L. Claesson-Welsh Minimal Active Domain and Mechanism of Action of the Angiogenesis Inhibitor Histidine-Rich Glycoprotein Cancer Res., February 15, 2006; 66(4): 2089 - 2097. [Abstract] [Full Text] [PDF]

				M. J. Hardman, A. Waite, L. Zeef, M. Burow, T. Nakayama, and G. S. Ashcroft Macrophage Migration Inhibitory Factor: A Central Regulator of Wound Healing Am. J. Pathol., December 1, 2005; 167(6): 1561 - 1574. [Abstract] [Full Text] [PDF]

				A. L. Jones, I. K. H. Poon, M. D. Hulett, and C. R. Parish Histidine-rich Glycoprotein Specifically Binds to Necrotic Cells via Its Amino-terminal Domain and Facilitates Necrotic Cell Phagocytosis J. Biol. Chem., October 21, 2005; 280(42): 35733 - 35741. [Abstract] [Full Text] [PDF]